학술논문
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
Document Type
Article
Author
Source
In: The Lancet Oncology . (The Lancet Oncology, May 2018, 19(5):649-659)
Subject
Language
English
ISSN
14745488
14702045
14702045